KPTI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Karyopharm Therapeutics Inc (KPTI) is not a strong buy at this time for a beginner investor with a long-term strategy. The stock shows overbought technical indicators, insider selling, and mixed analyst sentiment. While the company has shown some financial improvements, the lack of strong catalysts and the absence of Intellectia Proprietary Trading Signals suggest a cautious approach.
The stock is currently in an overbought condition with RSI_6 at 82.705. The MACD is positive at 0.336, indicating bullish momentum, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near its resistance level (R1: 8.687), which could limit further upside in the short term.
Gross margin remains strong at 95.65%. Analysts see potential upside if FDA approval for seli-rux in myelofibrosis is achieved.
Insider selling has increased by 599.43% over the last month. Analysts have lowered price targets significantly, with mixed sentiment on the company's drug pipeline. The stock has a 90% chance of declining -2.05% in the next week and -2.52% in the next month.
In Q4 2025, revenue increased by 11.58% YoY to $34.08M. Net income improved but remains negative at -$102.2M (up 232.03% YoY). EPS increased to -5.68 (up 54.77% YoY). Gross margin improved slightly to 95.65%.
Analysts have mixed views. RBC Capital, Baird, and H.C. Wainwright lowered price targets but maintain Outperform or Buy ratings. Piper Sandler and others highlight uncertainty around FDA approval for seli-rux, though some see potential upside if approval is achieved. Price targets range from $8 to $28, with recent reductions reflecting cautious sentiment.
